Research programme: G protein-coupled receptor modulators - Arena Pharmaceuticals/Taisho Pharmaceutical

Drug Profile

Research programme: G protein-coupled receptor modulators - Arena Pharmaceuticals/Taisho Pharmaceutical

Alternative Names: ATC 0021; ATC 0044; ATC 0065; ATC 0175 (AR 224349); ATC 0453; ATC 0759; GPCR modulators - Arena/Taisho

Latest Information Update: 21 Mar 2014

Price : $50

At a glance

  • Originator Arena Pharmaceuticals
  • Class Cyclohexylamines; Quinazolines; Small molecules
  • Mechanism of Action G protein-coupled receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Anxiety disorders; Major depressive disorder; Obesity; Sleep disorders

Most Recent Events

  • 07 May 2008 A lead compound from this programme has entered clinical development
  • 07 Nov 2007 Pharmacodynamics data from Preclinical trials in Anxiety and Depression presented at the 37th Annual Meeting of the Society for Neuroscience (SFN-2007)
  • 16 Jun 2005 Preclinical trials in Anxiety disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top